e-Drug3D
1865
LOFEXIDINE
INN
LOFEXIDINE
cas 31036-80-3
CLASS
NERVOUS SYSTEM
CENTRAL ALPHA-2 ADRENERGIC AGONIST
INDICATED FOR MITIGATION OF OPIOID WITHDRAWAL SYMPTOMS TO FACILITATE ABRUPT OPIOID DISCONTINUATION IN ADULTS
ROUTE (list)
ORAL
ATC code
N07BC04
PK parameters
F 72 PERCENT (0.36 MILLIGRAM)
Tmax 4 HOUR
VD 480 LITER
Cl 17.6 LITER / HOUR
PPB 55 PERCENT
t1/2 12 HOUR
Solubility
FREELY SOLUBLE IN WATER
TARGET ALPHA-2 ADRENERGIC RECEPTOR
Alpha-2A adrenergic receptor UNIPROT P08913 ADRA2A
Formula:
C11H12Cl2N2O
Calculated chemical properties:
MW 259.13
NB_atoms 16
XLogP 2.76
PSA 33.24
NB_HD 1
NB_HA 3
fsp3 0.36
Lipinski(0=no;1=yes) 1
NB_atoms 16
XLogP 2.76
PSA 33.24
NB_HD 1
NB_HA 3
fsp3 0.36
Lipinski(0=no;1=yes) 1
FDA
NDA 209229 (label) INN (LOFEXIDINE HYDROCHLORIDE) LUCEMYRA (BIOCORRX PHARMS) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY
NDA 218613 (pdf not found) INN (LOFEXIDINE HYDROCHLORIDE) LOFEXIDINE HYDROCHLORIDE (INDOCO) APPROVAL= AP YEAR= 2024
NDA 218699 (pdf not found) INN (LOFEXIDINE HYDROCHLORIDE) LOFEXIDINE HYDROCHLORIDE (MSN) APPROVAL= AP YEAR= 2025
NDA 209229 (label) INN (LOFEXIDINE HYDROCHLORIDE) LUCEMYRA (BIOCORRX PHARMS) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY
NDA 218613 (pdf not found) INN (LOFEXIDINE HYDROCHLORIDE) LOFEXIDINE HYDROCHLORIDE (INDOCO) APPROVAL= AP YEAR= 2024
NDA 218699 (pdf not found) INN (LOFEXIDINE HYDROCHLORIDE) LOFEXIDINE HYDROCHLORIDE (MSN) APPROVAL= AP YEAR= 2025